Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern
Long-term infliximab persistence was similar between switch and nonswitch cohorts over 4 years of follow-up. These data represent the longest duration of "real-world" follow-up, and should provide further reassurance that nonmedical switching is safe and clinically comparable to ongoing originator infliximab in clinically stable patients with IBD.
Authors
- Thomas Skinner (ORCID: https://orcid.org/0000-0001-9276-1955)
- Craig Haifer (ORCID: https://orcid.org/0000-0002-3675-6550)
- Ashish Srinivasan (ORCID: https://orcid.org/0000-0001-5952-1570)
- Daniel R. van Langenberg (ORCID: https://orcid.org/0000-0003-3662-6307)
- Simon Ghaly (ORCID: https://orcid.org/0000-0003-2489-6430)
- Lena Thin (ORCID: https://orcid.org/0000-0003-2816-3533)
- Shankar Menon
- James Winston
- Angus W. Jeffrey (ORCID: https://orcid.org/0000-0002-9137-0204)
- Yoon‐Kyo An (ORCID: https://orcid.org/0000-0002-1458-8015)
- Richard Fernandes (ORCID: https://orcid.org/0000-0002-9123-0228)
- Paulina Suo
- Nicholas Olsen
Institutions
- The University of Queensland (AU)
- The University of Western Australia (AU)
- Royal Perth Hospital (AU)
- Fiona Stanley Hospital (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Mater Research (AU)
- Eastern Health (AU)
- St Vincent’s Private Hospital Sydney (AU)
- Mater Adult Hospital (AU)
- Monash University (AU)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2025-02-27
- DOI
- https://doi.org/10.1111/jgh.16916
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of New South Wales